Pergolide
Pergolide
mesylate is a synthetic ergot derivative and is used in the treatment of
Parkinsonism as well as hyperprolactinaemia.
It
is an ergoline derivative, and a selective dopamine agonist with a high
affinity for the D2 receptor site, and a lesser affinity for the D1
receptor site.
Pergolide
is rapidly absorbed from the gastrointestinal tract, with peak plasma
concentrations occurring within 1 to 2 hours. At least 10 metabolites of
pergolide have been detected in the urine and faeces, including N-despropylpergolide,
pergolide sulfoxide, and pergolide sulfone.
Adverse
effects include somnolence, dyskinesias, nausea, dry mouth, constipation, and
hallucinations. Profound somnolence resulting in unplanned daytime sleep
episodes has occurred in an increasing number of patients receiving pergolide
as treatment of Parkinson’s disease. Dyskinesias were reported in 62.4% of
patients who received pergolide during a clinical trial, as compared with 24.6%
of patients who received placebo. Retroperitoneal fibrosis has been reported in
several patients following long-term pergolide therapy. There are some reports
of erythromelalgia of the lower extremities in Parkinsonian patients on
pergolide therapy. Pleuropulmonary fibrosis was reported in several patients
following long-term pergolide therapy.
Overdose
with pergolide may result in vomiting, sweating, dizziness, agitation,
dyskinesias, hallucinations, involuntary movements, palpitations, and
hypotension. Treatment is symptomatic.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.